中华男科学杂志

参考文献

[1] Gu FL,Xia TL,Kong XT.Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China.Urology,1994,44(5):688-691.

[2] Abrams P,Cardozo L,Fall M,et al.The standardisation of terminology in lower urinary tract function:Report from the standardisation sub-committee of the International Continence Society.Urology,2003,61(1):37-49.

[3] Martin SA,Haren MT,Marshall VR,et al.Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.World J Urol,2011,29(2):179-184.

[4] Agarwal A,Eryuzlu LN,Cartwright R,et al.What is the most bothersome lower urinary tract symptom?Individual- and population-level perspectives for both men and women.Eur Urol,2014,65(6):1211-1217.

[5] Calogero AE,Burgio G,Condorelli RA,et al.Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.Aging Male,2019,22(1):12-19.

[6] Chapple CR,Roehrborn CG.A shifted paradigm for the further understanding,evaluation,and treatment of lower urinary tract symptoms in men:focus on the bladder.Eur Urol,2006,49(4):651-658.

[7] De Nunzio C,Roehrborn CG,Andersson KE,et al.Erectile dysfunction and lower urinary tract symptoms.Eur Urol Focus,2017,3(4-5):352-363.

[8] Roehrborn CG,Bartsch G,Kirby R,et al.Guidelines for the diagnosis and treatment of benign prostatic hyperplasia:A comparative,international overview.Urology,2001,58(5):642-650.

[9] Comiter CV,Sullivan MP,Schacterle RS,et al.Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction.J Urol,1997,158(1):181-185.

[10] El Din KE,Kiemeney LA,De Wildt MJ,et al.The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score.J Urol,1996,156(3):1020-1025.

[11] Stohrer M,Blok B,Castro-Diaz D,et al.EAU guidelines on neurogenic lower urinary tract dysfunction.Eur Urol,2009,56(1):81-88.

[12] 张亚群，王劲夫，陈鑫，等.前列腺突入膀胱长度与下尿路症状关系的单中心分析.中国医刊，2018,53(3):297-299.

[13] Gacci M,Corona G,Salvi M,et al.A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol,2012,61(5):994-1003.

[14] Wang Y,Bao Y,Liu J,et al.Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction:A systematic review and meta-analysis.Low Urin Tract Symptoms,2018,10(1):84-92.

[15] Michel MC,Vrydag W.Alpha1-,alpha2- and beta-adrenoceptors in the urinary bladder,urethra and prostate.Br J Pharmacol,2006,147(Suppl 2):S88-S119.

[16] Roehrborn CG,Siami P,Barkin J,et al.The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia:4-year results from the CombAT study.Eur Urol,2010,57(1):123-131.

[17] Roehrborn CG,Siami P,Barkin J,et al.The effects of dutasteride,tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement:2-year results from the CombAT study.J Urol,2008,179(2):616-621.

[18] Barendrecht MM,Abrams P,Schumacher H,et al.Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?Neurourol Urodyn,2008,27(3):226-230.

[19] Nickel JC,Sander S,Moon TD.A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.Int J Clin Pract,2008,62(10):1547-1559.

[20] Barendrecht MM,Koopmans RP,De La Rosette JJ,et al.Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia:The cardiovascular system.BJU Int,2005,95(Suppl 4):19-28.

[21] Chang DF,Campbell JR.Intraoperative floppy iris syndrome associated with tamsulosin.J Cataract Refract Surg,2005,31(4):664-673.

[22] Abdel-Aziz S,Mamalis N.Intraoperative floppy iris syndrome.Curr Opin Ophthalmol,2009,20(1):37-41.

[23] Wilkinson AG,Wild SR.Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism?Br J Urol,1992,70(1):53-57.

[24] Andriole G,Bruchovsky N,Chung LW,et al.Dihydrotestosterone and the prostate:The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.J Urol,2004,172(4):1399-1403.

[25] Rittmaster RS,Norman RW,Thomas LN,et al.Evidence for atrophy and apoptosis in the prostates of men given finasteride.J Clin Endocrinol Metab,1996,81(2):814-819.

[26] Naslund MJ,Miner M.A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.Clin Ther,2007,29(1):17-25.

[27] Bruskewitz R,Girman CJ,Fowler J,et al.Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia.PLESS Study Group.Proscar Long-term Efficacy and Safety Study.Urology,1999,54(4):670-678.

[28] Mcconnell JD,Roehrborn CG,Bautista OM,et al.The long-term effect of doxazosin,finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia.N Engl J Med,2003,349(25):2387-2398.

[29] Andriole GL,Guess HA,Epstein JI,et al.Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer:Results of a randomized,double-blind,placebo-controlled clinical trial.PLESS Study Group.Proscar Long-term Efficacy and Safety Study.Urology,1998,52(2):195-201.

[30] Thompson IM,Goodman PJ,Tangen CM,et al.The influence of finasteride on the development of prostate cancer.N Engl J Med,2003,349(3):215-224.

[31] Andriole GL,Bostwick DG,Brawley OW,et al.Effect of dutasteride on the risk of prostate cancer.N Engl J Med,2010,362(13):1192-1202.

[32] Chess-Williams R,Chapple CR,Yamanishi T,et al.The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.J Auton Pharmacol,2001,21(5-6):243-248.

[33] Matsui M,Motomura D,Karasawa H,et al.Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype.Proc Natl Acad Sci USA,2000,97(17):9579-9584.

[34] Yamada S,Kuraoka S,Osano A,et al.Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.Int Neurourol J,2012,16(3):107-115.

[35] Morelli A,Sarchielli E,Comeglio P,et al.Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.J Sex Med,2011,8(10):2746-2760.

[36] Giuliano F,Uckert S,Maggi M,et al.The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.Eur Urol,2013,63(3):506-516.

[37] Vignozzi L,Gacci M,Cellai I,et al.PDE5 inhibitors blunt inflammation in human BPH:A potential mechanism of action for PDE5 inhibitors in LUTS.Prostate,2013,73(13):1391-1402.

[38] Takasu T,Ukai M,Sato S,et al.Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178),a novel selective beta3-adrenoceptor agonist,on bladder function.J Pharmacol Exp Ther,2007,321(2):642-647.

[39] Chapple CR,Kaplan SA,Mitcheson D,et al.Randomized double-blind,active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron,a beta(3)-adrenoceptor agonist,in overactive bladder.Eur Urol,2013,63(2):296-305.

[40] Herschorn S,Barkin J,Castro-Diaz D,et al.A phase III,randomized,double-blind,parallel-group,placebo-controlled,multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist,mirabegron,in patients with symptoms of overactive bladder.Urology,2013,82(2):313-320.

[41] Khullar V,Amarenco G,Angulo J C,et al.Efficacy and tolerability of mirabegron,a beta(3)-adrenoceptor agonist,in patients with overactive bladder:Results from a randomised European-Australian phase 3 trial.Eur Urol,2013,63(2):283-295.

[42] Nitti VW,Auerbach S,Martin N,et al.Results of a randomized phase III trial of mirabegron in patients with overactive bladder.J Urol,2013,189(4):1388-1395.

[43] 商学军，耿强，段建敏，等.龙金通淋胶囊治疗Ⅲ型前列腺炎的疗效与安全性研究.中华男科学杂志，2014,20(12):1109-1112.

[44] 宁泌泰胶囊临床应用中国专家共识编写组.宁泌泰胶囊在下尿路症状中临床应用中国专家共识.中华男科学杂志，2017,23(9):852-855.

[45] 中国中医药信息研究会男科分会.黄莪胶囊在良性前列腺增生临床应用中国专家共识.中华男科学杂志，2018,24(10):945-948.

[46] 高筱松，吴佳寅，韩万峰，等.夏荔芪胶囊治疗良性前列腺增生多中心双盲双模拟阳性药对照试验研究.北京中医药，2020,39(7):745-749.

[47] 孟繁超，李海松，赵琦，等.灵泽片治疗良性前列腺增生症真实世界临床应用的疗效观察.中国男科学杂志，2021,35(4):40-44.

[48] 中华中医药学会男科分会.前列舒通胶囊治疗良性前列腺增生临床应用专家共识.中华男科学杂志，2020,26(8):759-762.

[49] 罗小冬，王德权，郭猛，等.前列欣胶囊改善前列腺增生患者排尿症状的疗效观察.中国男科学杂志，2007,21(6):54.

[50] 马进华，魏红兵，李先林，等.前列金丹片联合多沙唑嗪治疗良性前列腺增生的疗效观察.现代药物与临床，2020,35(5):980-983.

[51] 张春和，李曰庆，裴晓华，等.良性前列腺增生症中医诊治专家共识.北京中医药，2016,35(11):1076-1080.

[52] 吕燊，曹挺威.普乐安片治疗前列腺增生疗效的 Meta 分析.中国临床药理学与治疗学，2012,17(2):195-198.

[53] Riedinger CB,Fantus RJ,Matulewicz RS,et al.The impact of surgical duration on complications after transurethral resection of the prostate:An analysis of NSQIP data.Prostate Cancer Prostatic Dis,2019,22(2):303-308.

[54] Bansal A,Sankhwar S,Kumar M,et al.Holmium laser vs monopolar electrocautery bladder neck incision for prostates less than 30 grams:A prospective randomized trial.Urology,2016,93:158-163.

[55] Lourenco T,Shaw M,Fraser C,et al.The clinical effectiveness of transurethral incision of the prostate:A systematic review of randomised controlled trials.World J Urol,2010,28(1):23-32.

[56] Skolarikos A,Papachristou C,Athanasiadis G,et al.Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc.J Endourol,2008,22(10):2333-2340.

[57] Naspro R,Suardi N,Salonia A,et al.Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g:24-month follow-up.Eur Urol,2006,50(3):563-568.

[58] Middleton LW,Shen Z,Varma S,et al.Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.JCI Insight,2019,5.

[59] Chen YB,Chen Q,Wang Z,et al.A prospective,randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup.J Urol,2013,189(1):217-222.

[60] Gilling PJ,Kennett K,Das AK,et al.Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation:An update on the early clinical experience.J Endourol,1998,12(5):457-459.

[61] Ruszat R,Wyler S,Forster T,et al.Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation.Eur Urol,2007,51(4):1031-1038.

[62] Bouchier-Hayes DM,Van Appledorn S,Bugeja P,et al.A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy,with a 1-year follow-up.BJU Int,2010,105(7):964-969.

[63] Capitan C,Blazquez C,Martin MD,et al.GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia:A randomized clinical trial with 2-year follow-up.Eur Urol,2011,60(4):734-739.

[64] Bach T,Muschter R,Sroka R,et al.Laser treatment of benign prostatic obstruction:Basics and physical differences.Eur Urol,2012,61(2):317-325.

[65] Jiang H,Zhou Y.Safety and efficacy of thulium laser prostatectomy versus transurethral resection of prostate for treatment of benign prostate hyperplasia:A meta-analysis.Low Urin Tract Symptoms,2016,8(3):165-170.

[66] Gu M,Liu C,Chen YB,et al.Comparison of vela and holmium laser enucleation of the prostate:A retrospective clinical trial with a 12-month follow-up.Int Urol Nephrol,2018,50(5):819-823.

[67] Zhang J,Wang X,Zhang Y,et al.1470 nm diode laser enucleation vs plasmakinetic resection of the prostate for benign prostatic hyperplasia:A randomized study.J Endourol,2019,33(3):211-217.

[68] Zou Z,Xu A,Zheng S,et al.Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs.bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction:1-year follow-up results.World J Urol,2018,36(7):1117-1126.

[69] 许凯，刘春晓.经尿道双极等离子体前列腺剜除术治疗良性前列腺增生症1100例.实用医学杂志，2012,28(14):2395-2397.

[70] 刘俊峰，刘春晓，谭朝晖，等.经尿道双极等离子前列腺剜除术与电切术后尿失禁发生率的随机对照研究.中华男科学杂志，2014,20(2):165-168.

[71] Autorino R,Damiano R,Di Lorenzo G,et al.Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate.Eur Urol,2009,55(4):922-929.

[72] Xie L,Mao Q,Chen H,et al.Transurethral vapor enucleation and resection of the prostate with plasma vaporization button electrode for the treatment of benign prostatic hyperplasia:A feasibility study.J Endourol,2012,26(10):1264-1266.

[73] 谢立平，陈弘.前列腺增生腔内剜除手术方法探讨.临床泌尿外科杂志，2016,31(6):489-492.

[74] Zhang K,Sun D,Zhang H,et al.Plasmakinetic vapor enucleation of the prostate with button electrode versus plasmakinetic resection of the prostate for benign prostatic enlargement >90 ml:Perioperative and 3-month follow-up results of a prospective,randomized clinical trial.Urol Int,2015,95(3):260-264.

[75] Catania JA,Oakley LP,Rosen R,et al.Effects of interview mode on assessments of erectile and ejaculatory dysfunction among men with benign prostatic hyperplasia (BPH).J Sex Res,2013,50(6):524-536.

[76] Li Z,Chen P,Wang J,et al.The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function:A systematic review and network meta-analysis.Medicine,2016,95(24):e3862.

[77] Leong JY,Patel AS,Ramasamy R.Minimizing sexual dysfunction in BPH surgery.Curr Sex Health Reports,2019,11(3):190-200.

[78] Liu Y,Cheng Y,Zhuo L,et al.Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia:A systematic review and meta-analysis.J Endourol,2020,34(10):1064-1074.

[79] Lebdai S,Chevrot A,Doizi S,et al.Do patients have to choose between ejaculation and miction?A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment.World J Urol,2019,37(2):299-308.

[80] Verze P,Califano G,Sokolakis I,et al.The impact of surgery for lower urinary tract symptoms/benign prostatic enlargement on both erectile and ejaculatory function:A systematic review.Int J Impot Res,2019,31(5):319-327.

[81] Marra G,Sturch P,Oderda M,et al.Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function:Time for a bespoke approach?Int J Urol,2016,23(1):22-35.

[82] Hawker G A,Mian S,Kendzerska T,et al.Measures of adult pain:Visual Analog Scale for Pain (VAS Pain),Numeric Rating Scale for Pain (NRS Pain),McGill Pain Questionnaire (MPQ),Short-Form McGill Pain Questionnaire (SF-MPQ),Chronic Pain Grade Scale (CPGS),Short Form-36 Bodily Pain Scale (SF-36 BPS),and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).Ar Care Res,2011,63(Suppl 11):S240-S252.

[83] 赵军，贺大林，刘润明，等.良性前列腺增生相关的膀胱痉挛病因分析及治疗.中华男科学杂志，2005,11(4):275-277.

[84] Zhang B,Wei J,Wu X,et al.Clinical optimal dose of solifenacin succinate for nursing patients after transurethral resection of the prostate during the perioperative period.Exp Ther Med,2018,15(2):1660-1665.

[85] Peng XF,Lv XG,Xie H,et al.Effectiveness of solifenacin for managing of bladder spasms in patients with urethroplasty.Am J Mens Health,2017,11(5):1580-1587.

[86] Liang D,Jin S,Huang L,et al.The effect of transcutaneous electrical acupoint stimulation on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of the prostate.Evid Based Complement Alternat Med,2021,2021:6691459.

[87] 万祥，刘冲，徐欢，等.“3+1”膀胱功能恢复法联合剜除术治疗良性前列腺增生合并逼尿肌无力的初步探索.中华男科学杂志，2017,23(10):912-916.

[88] Toia B,Gresty H,Pakzad M,et al.Bulking for stress urinary incontinence in men:A systematic review.Neurourol Urodyn,2019,38(7):1804-1811.

[89] Imamoglu MA,Tuygun C,Bakirtas H,et al.The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence.Eur Urol,2005,47(2):209-213.

[90] Alloussi SH,Lang C,Eichel R,et al.Ejaculation-preserving transurethral resection of prostate and bladder neck:Short- and long-term results of a new innovative resection technique.J Endourol,2014,28(1):84-89.

[91] Lee JY,Park SY,Jeong TY,et al.Combined tadalafil and alpha-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction:A multicenter,prospective study.J Androl,2012,33(3):397-403.

[92] 李韬，谢子平，谭艳，等.阴茎负压吸引联合小剂量他达拉非治疗糖尿病性勃起功能障碍的临床观察.中国性科学，2016,25(11):8-10.

[93] Martinez DR,Terlecki R,Brant WO.The evolution and utility of the small-carrion prosthesis,its impact,and progression to the modern-day malleable penile prosthesis.J Sex Med,2015,12(Suppl 7):423-430.

[94] 陈彦博，陈其，谷猛，等.经尿道前列腺钬激光剜除术日间手术24例临床报告.现代泌尿外科杂志，2017,22(5):331-335.

[95] 夏术阶，吕福泰，辛钟成.郭应禄男科学.第2版.北京：人民卫生出版社，2019.1084.

[96] 黄健.中国泌尿外科和男科疾病诊断治疗指南.北京：科学出版社，2019.236.

[97] Giovanni S,Andrea P,Maria PG,et al.Impact of thulium laser enucleation of the prostate on erectile,ejaculatory and urinary functions.Urol Int,2016,97(4):397-401.

[98] Mykoniatis I,Sokolakis I,Renterghem KV.How can we preserve sexual function after ablative surgery for benign prostatic hyperplasia?Curr Drug Targets,2021,22(1):4-13.